X4 Pharmaceuticals, Inc
XFOR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001501697
In the last 90 days, X4 Pharmaceuticals, Inc insiders filed 0 open-market purchases and 2 sales; 89 institutions reported holding it in 13F filings for Q2 2026, worth $463.0M in total; no superinvestor holds it.
Q1 2026 vs. Q4 2025
How the institutions holding X4 Pharmaceuticals, Inc changed between Q4 2025 and Q1 2026.
All holders in Q1 2026All holders in Q4 2025
| Measure | Q4 2025 | Of which not filed for Q1 2026 | Q1 2026 | Change |
|---|---|---|---|---|
| Holders | 79 | 2 | 84 | +7 |
| Shares | 89.4M | 3.43M | 93.9M | +7.90M (+9.2%) |
| Value | $357.7M | $13.7M | $388.1M | +$44.1M (+12.8%) |
2 institutions that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so the changes leave them out.
New holders (18)
Institutions that held X4 Pharmaceuticals, Inc at the end of Q1 2026 but not at the end of Q4 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Vanguard Capital Management LLC | 3,497,612 | $14.4M | 0.00% |
| Vanguard Fiduciary Trust Co | 480,733 | $1.99M | 0.00% |
| VR Adviser, LLC | 330,525 | $1.37M | 0.05% |
| Brevan Howard Capital Management LP | 127,321 | $525.8K | 0.01% |
| Dynamic Technology Lab Private Ltd | 36,221 | $384.7K | 0.06% |
| Catalyst Funds Management Pty Ltd | 47,383 | $195.7K | 0.03% |
| Vanguard Global Advisers, LLC | 32,977 | $136.2K | 0.00% |
| Diametric Capital, LP | 28,973 | $119.7K | 0.03% |
| Invesco Ltd. | 19,968 | $82.5K | 0.00% |
| Schonfeld Strategic Advisors LLC | 19,514 | $80.6K | 0.00% |
| Jump Financial, LLC | 12,317 | $50.9K | 0.00% |
| JustInvest LLC | 11,525 | $47.6K | 0.00% |
| SummitTX Capital, L.P. | 11,200 | $46.3K | 0.00% |
| Winton Group Ltd | 10,600 | $43.8K | 0.00% |
| State of Wyoming | 1,065 | $4.40K | 0.00% |
| Acadian Asset Management LLC | 802 | $3.00K | 0.00% |
| Quadrant Capital Group LLC | 128 | $529 | 0.00% |
| Parallel Advisors, LLC | 116 | $479 | 0.00% |
Sold out (11)
Institutions that held X4 Pharmaceuticals, Inc at the end of Q4 2025 and filed for Q1 2026 without it.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Siren, L.L.C. | 1,500,000 | $6.00M |
| Point72 Asset Management, L.P. | 808,154 | $3.23M |
| Silverarc Capital Management, LLC | 357,387 | $1.43M |
| Citadel Advisors LLC | 128,675 | $514.7K |
| Balyasny Asset Management LLC | 64,505 | $258.0K |
| Man Group plc | 24,187 | $96.7K |
| Lighthouse Investment Partners, LLC | 22,200 | $88.8K |
| Squarepoint Ops LLC | 12,518 | $50.1K |
| Fortitude Family Office, LLC | 137 | $548 |
| GWM Advisors LLC | 33 | $132 |
| RMG Wealth Management LLC | 28 | $64 |
Not filed for Q1 2026 yet (2)
Institutions that held X4 Pharmaceuticals, Inc at the end of Q4 2025 and haven't filed a 13F for Q1 2026. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Vanguard Group Inc | 3,423,662 | $13.7M |
| CIBC Private Wealth Group, LLC | 2,166 | $8.66K |